BioPharma Dive January 23, 2025
In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and Alnylam in a closely watched commercial battle.
Neil Kumar has for years contended his unorthodox drug company is overlooked by biotechnology investors. He may not have that problem for much longer.
The company he leads, BridgeBio Pharma, is in the early stages of launching a treatment for a heart condition called transthyretin amyloidosis with cardiomyopathy. Though the drug, Attruby, isn’t BridgeBio’s only approved product, it has the largest financial upside.
Global sales of the other marketed therapy for the condition, Pfizer’s tafamidis, were on track to eclipse $5 billion last year, reflecting a market that analysts forecast could eventually be...
Today's Sponsors
Today's Sponsor